Mind + Muscle

technical minds + legal muscle


dig deep

Hospira Can't Get Helsinn Aloxi Suit Dismissed

  • 04.08.16
  • Dana A. Elfin
  • Bloomberg BNA Pharmaceutical Law & Industry Report

Paul A. Ainsworth, director in the firm’s Litigation Group, is quoted in the "Government" section of Bloomberg BNA’s article, “Hospira Can't Get Helsinn Aloxi Suit Dismissed.”

In the article, Mr. Ainsworth discusses the notable decision made by the U.S. District Court for the District of New Jersey in Helsinn Healthcare S.A. v. Hospira, Inc., in which the Court decided not to dismiss Helsinn Healthcare’s patent infringement complaint against Hospira.

“The New Jersey court's decision in Helsinn v. Hospira is predictably in line with the Federal Circuit's latest ruling in Acorda,” said Mr. Ainsworth. The result in the case is not surprising because the Federal Circuit's analysis relied on facts that are typical to most, if not all, ANDA filers, he continued.

Click the link below to see the full article on pages 8-9 (506-507 in Bloomberg BNA).
[Reproduced with permission from Pharmaceutical Law & Industry Report, 14 PLIR 506 (Apr. 8, 2016). Copyright 2016 by The Bureau of National Affairs, Inc. (800-372-1033) <http://www.bna.com>]

Related People

Related Services

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.